This season’s Game of Thrones finished last night and as a nephrology-themed homage, a trainee from Malaysia, Lee Jun, created this poster during downtime while studying for his exams. Enjoy.
I saw a 20 year old African American male in clinic with nephrotic range proteinuria, reduced GFR and no signs or symptoms of a systemic disease. His mother developed ESRD at age 36 and his brother, aged 26,…
A few months ago, a paper was published in the International Journal of Epidemiology that caused a sensation in it’s home country – Denmark. Using registry data, and the diagnosis of non-melanomatous skin cancer as a proxy for…
File this under something that we are never likely to see in clinical practice. In 2002 a fascinating case report was published in the New England Journal of Medicine concerning unusual findings during a work-up for a living…
Tomorrow night will be the 4th edition of the Nephrology Journal Club on twitter.The article this week is unusual – it is a clinical practice guideline for the management of hyponatremia that was published in NDT, the European…
In the USA in June 2013 the OPTN/UNOS Board of Directors approved amendments to the OPTN policy for deceased donor kidney allocation. These ideas have been discussed for the last 9 years and Nate wrote about some of…
All to often now doctors in well-resourced hospitals rely on high tech, expensive and sometimes invasive tests to make a diagnosis. One of the most basic and cheapest tools we have at our disposal is the bedside urine…
Over at eAJKD, Swapnil Hiremath has a nice post about the potential for SGLT-2 inhibitors to prevent diabetic nephropathy based on a review article published on the topic in AJKD. Essentially the theory is that increased serum glucose…
It’s time for a quick nephro-centric summary of immune globulin use. Immune globulin, usually administered intravenously (IVIg), is made from pooled human plasma and used for a wide variety of human disease. It contains mostly IgG with various…
The next Nephrology Twitter Journal Club (@NephJC) will discuss a study in JASN describing the use of Atrasentan, a selective Endothelin-A receptor blocker, in diabetic kidney disease. This is the latest attempt to resurrect this class of agents…